ERBB2 and breast cancer: Despite the good prognosis of early-stage BC expressing oestrogen receptor (ER) and lacking human epidermal growth factor receptor 2 (HER2) overexpression (luminal BC), post-treatment recurrence occurs in approximately 20% of cases [2].